Efficacy and safety of apixaban for the primary prevention of VTE among patients with gastrointestinal cancers: a post-hoc analysis of the AVERT trial

Pas encore traduit Pas encore traduit
Catégorie Primary study
ConférenceInternational Society on Thrombosis and Haemostasis Congress; United States. Published in: Research and practice in thrombosis and haemostasis.
Year 2022
Loading references information
Cet article n'a pas de résumé
Epistemonikos ID: 4bf2776162c1142b8dc38e1fe8b870fd80178a79
First added on: Jun 08, 2022